Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma

Journal of Clinical Microbiology

Volumn 37, Issue 8, 1999, Pages 2428-2433

  Kirstein, Lynn M ^a   Mellors, John W ^b   Rinaldo Jr , Charles R ^b   Margolick, Joseph B ^a   Giorgi, Janis V ^c   Phair, John P ^d   Dietz, Edith ^a   Gupta, Phalguni ^b   Sherlock, Christopher H ^e   Hogg, Robert ^e   Montaner, J S G ^e   Muñoz, Alvaro ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EDETIC ACID; HEPARIN; VIRUS RNA;

ANTICOAGULATION; ARTICLE; ASSAY; BLOOD ANALYSIS; BLOOD SAMPLING; BLOOD STORAGE; DIAGNOSTIC ACCURACY; HEPARINIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032767618     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.8.2428-2433.1999     Document Type: Article

References (29)

1. Boyko, W. J., M. T. Schechter, E. Jeffries, B. Douglas, M. Maynard, and M. O'Shaughnessy. 1985. The Vancouver Lymphadenopathy-AIDS Study. 3. Relation of HTLV-III seropositivity, immune status, and lymphadenopathy. Can. Med. Assoc. J. 133:28-32.
2. Brambilla, D., S. Leung, J. Lew, J. Todd, S. Herman, M. Cronin, D. E. Shapiro, J. Bremer, C. Hanson, G. V. Hillyer, G. D. McSherry, R. S. Sperling, R. W. Coombs, P. S. Reichelderfer, L. Kalish, and D. E. Shapiro. 1998. Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 in plasma: effect of an external standard on kit comparisons. J. Clin. Microbiol. 36:311-314.
3. Centers for Disease Control and Prevention. 1998. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. Morbid. Mortal. Weekly Rep. 47(No. RR-5):1-82.
4. Coombs, R. W., D. R. Henrard, W. F. Mehaffey, J. Gibson, E. Eggert, T. C. Quinn, and J. Phillips. 1993. Cell-free plasma human immunodeficiency virus type 1 liter assessed by culture and immunocapture-reverse transcription-polymerase chain reaction. J. Clin. Microbiol. 31:1980-1986.
5. Coombs, R. W., S. L. Welles, C. Hooper, P. S. Reichelderfer, R. T. D'Aquila, A. J. Japoyr, V. A. Johnson, D. R. Kuritzkes, D. D. Richman, S. Kwok, J. Todd, J. B. Jackson, V. DeGruttola, C. S. Crumpacker, and J. Kahn. 1996. Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J. Infect. Dis. 174:704-712.
6. Detels, R., A. Muñoz, G. McFarlane, L. A. Kingsley, J. B. Margolick, J. V. Giorgi, L. K. Schrager, and J. P. Phair for the Multicenter AIDS Cohort Study. 1998. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 17:1487-1503.
7. Dickover, R. E., S. A. Herman, K. Saddiq, D. Wafer, M. Dillon, and Y. J. Bryson. 1998. Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR. J. Clin. Microbiol. 36:1070-1073.
8. Dyer, J. R., C. D. Pilcher, R. Shepard, J. Schock, J. J. Eron, and S. A. Fiscus. 1999. Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 37:447-449.
9. Ginocchio, C. C., X. P. Wang, M. H. Kaplan, G. Mulligan, D. Witt, J. W. Romano, M. Cronin, and R. Carroll. 1997. Effects of specimen collection, processing, and storage conditions on the stability of human immunodeficiency virus type 1 RNA levels in plasma. J. Clin. Microbiol. 35:2886-2893.
10. Giorgi, J. V., H. L. Cheng, J. B. Margolick, K. D. Bauer, J. Ferbase, M. Waxdal, I. Schmid, L. E. Hultin, A. L. Jackson, L. Park, J. M. G. Taylor, and the Multicenter AIDS Cohort Study Group. 1990. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort Study experience. Clin. Immunol. Immunopathol. 55:173-186.
11. Griffith, B. P., M. O. Rigsby, R. B. Garner, M. M. Gordon, and T. M. Chacko. 1997. Comparison of the Amplicor HIV-1 monitor test and the nucleic acid sequence-based amplification assay for quantitation of human immunodeficiency virus RNA in plasma subjected to freeze-thaw cycles. J. Clin. Microbiol. 35:3288-3291.
12. Hogg, R. S., K. V. Heath, B. Yip, K. J. P. Craib, M. V. O'Shaughnessy, M. T. Schechter, and J. S. G. Montaner, 1998. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279: 450-454.
13. Holodniy, M., S. Kim, D. A. Katzenstein, M. Konrad, E. Groves, and T. C. Merigan. 1991. Inhibition of human immunodeficiency virus gene amplification by heparin. J. Clin. Microbiol. 29:676-679.
14. Holodniy, M., L. Mole, B. Yen-Lieberman, D. Margolis, C. Starkey, R. Carroll, T. Spahlinger, J. Todd, and J. B. Jackson. 1995. Comparative stabilities of quantitative human immunodeficiency virus RNA from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J. Clin. Microbiol. 33:1562-1566.
15. Kaslow, R. A., D. G. Ostrow, R. Detels, J. P. Phair, B. F. Polk, and C. R. Rinaldo. 1984. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am. J. Epidemiol. 126:310-318.
16. Kempf, D. J., R. A. Rode, Y. Xu, E. Sun, M. E. Heath-Chiozzi, J. Valdes, A. J. Japour, S. Danner, C. Boucher, A. Molla, and J. M. Leonard. 1998. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 12:F9-F14.
17. Mellors, J. W. 1998. The role of new technologies in managing antiretroviral therapy. In Program at the 12th World AIDS Conference Agouron Satellite Symposium.
18. + lymphocytes as prognostic markers of HIV infection. Ann. Intern. Med. 126:946-954.
19. Metcalf, J. A., R. T. Davey, Jr., and H. C. Lane. 1997. Acquired immunodeficiency syndrome: serologic and virologic tests, p. 189-193. In V. T. DeVita, S. Hellman, and S. A. Rosenberg (ed.), AIDS: etiology, diagnosis, treatment, and prevention, 4th ed. J. B. Lippincott, Philadelphia, Pa.
20. Mole, L., D. Margols, R. Carroll, J. Todd, and M. Holodniy. 1994. Stability of quantitative human immunodeficiency virus plasma culture, RNA, and p24 antigen from samples collected in VACUTAINER CPT versus standard VACUTAINER tubes. J. Clin. Microbiol. 32:2212-2215.
21. Mulder, J., N. McKinney, C. Christophersonb, J. Sninsky, L. Greenfield, and S. Kwok. 1994. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.
22. + lymphocyte counts and the risk of progression to AIDS. N. Engl. J. Med. 334:426-431.
23. O'Shea, S. T. Rostron, J. E. Mullen, and J. E. Banatvala. 1994. Stability of infectious HIV in clinical samples and isolation from small volumes of whole blood. J. Clin. Pathol. 47:152-154.
24. Pachl, C., J. A. Todd, D. G. Kern, P. J. Sheridan, S. J. Fong, M. Stempien, B. Hoo, D. Besemer, T. Yeghiazarian, B. Irvine, J. Kolberg, R. Kokka, P. Neuwald, and M. S. Urdea. 1995. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. Acquired Immune Defic. Syndr. 8:446-454.
25. Raboud, J. M., J. S. G. Montaner, B. Conway, S. Rae, P. Reiss, S. Vella, D. Cooper, J. Lange, M. Harris, M. A. Wainberg, P. Robinson, M. Myers, and D. Hall. 1998. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS 12:1619-1624.
26. Todd, J., C. Pachl, R. White, T. Yeghiazarian, P. Johnson, B. Taylor, M. Holodniy, D. Kern, S. Hamren, D. Chernoff, and M. Urdea. 1995. Performance characteristics for the quantitation of plasma HIV RNA using branched DNA signal amplification technology. J. Acquired Immune Defic. Syndr. 10(Suppl. 2):S35-S44.
27. Vandamme, A. M., J. C. Schmit, S. Van Dooren, K. Van Laethem, E. Gobbers, W. Kok, P. Goubau, M. Witvrouw, W. Peetermans, E. De Clercq, and J. Desmyter. 1996. Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV Monitor test. J. Acquired Immune Defic. Syndr. 13:127-139.
28. van Gemen, B., R. van Beuningen, A. Nabbe, D. van Strijp, S. Jurriaans, P. Lens, and T. Kievits. 1994. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescence (ECL) labeled probes. J. Virol. Methods 49:157-167.
29. Yen-Lieberman, B., D. Brambilla, B. Jackson, J. Bremer, R. Coombs, M. Cronin, S. Herman, D. Katzenstein, S. Leung, H. J. Lin, P. Palumbo, S. Rasheed, J. Todd, M. Vahey, and P. Reichelderfer. 1996. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J. Clin. Microbiol. 34:2695-2701.